Travere Therapeutics, Inc. is rated a Buy, secured full FDA approval for Filspari in FSGS, and driving a 37% stock surge.
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
Investor's Business Daily on MSN
Travere Therapeutics sees its composite rating rise to 97
Travere Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 97.
Filspari is now indicated for patients with focal segmental glomerulosclerosis without nephrotic syndrome to target significant proteinuria reduction.
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...
Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
A once-daily oral tablet, sparsentan is fully approved to reduce proteinuria in patients ages 8 and older with FSGS who do ...
Becoming the first and only fully FDA-approved treatment for focal segmental glomerulosclerosis (FSGS), Travere Therapeutics Inc.’s Filspari (sparsentan) has gained access to a second lucrative market ...
Recent health news highlights significant regulatory and technological advancements in the medical field. South Korea bans syringe stockpiling due to supply concerns amid the Iran conflict, while U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results